13F Holdings
中文EN

EMBC Embecta Corp.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1872789 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-7.6%
TTM net income YoY4.7%
TTM EPS YoY3.5%
Revenue 3-yr CAGR-2.9%
Net income 3-yr CAGR22.8%

Margins

Gross margin59.0%
Operating margin21.9%
Net margin8.6%
FCF margin16.2%
EBITDA margin26.3%

Returns

ROE—
ROA7.2%
ROIC (approx.)26.2%
Asset turnover0.84x

Leverage & solvency

Liabilities / assets148.4%
Debt / equity—
Current ratio1.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.99x
Accruals ratio-7.1%
Payout ratio31.1%
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30FY20212021-09-30
Income statement
Revenue$1.08B$1.12B$1.12B$1.13B$1.17B
Cost of revenue$403.60M$387.90M$370.90M$354.60M$364.90M
Gross profit$676.80M$735.20M$749.90M$774.90M$800.40M
R&D expense$37.30M$78.80M$85.20M$66.90M$63.30M
SG&A expense$332.00M$365.10M$341.30M$294.80M$240.30M
Operating income$242.10M$166.80M$221.50M$309.60M$492.00M
Pretax income$136.30M$44.20M$105.70M$256.60M$494.90M
Income tax$40.90M-$34.10M$35.30M$33.00M$80.10M
Net income$95.40M$78.30M$70.40M$223.60M$414.80M
EBITDA$282.80M$203.00M$254.10M$341.30M$530.30M
EPS (basic)1.641.361.233.927.28
EPS (diluted)1.621.341.223.897.28
Dividends declared per share0.600.600.600.15—
Weighted avg. shares (diluted)58.91M58.33M57.76M57.46M57.01M
Balance sheet
Cash & equivalents$225.50M$274.20M$326.50M$330.90M$0
Receivables$145.60M$193.00M$16.70M$22.20M$150.60M
Inventory$178.60M$171.50M$152.10M$122.80M$118.00M
Current assets$631.40M$761.00M$749.10M$664.70M$291.80M
PP&E, net$257.20M$290.40M$300.20M$301.60M$450.90M
Goodwill$15.40M$15.60M$15.60M$15.70M$15.60M
Intangibles$7.00M$8.10M$9.10M$8.90M$18.30M
Total assets$1.09B$1.29B$1.21B$1.09B$788.00M
Current liabilities$261.50M$374.00M$353.50M$301.00M$164.00M
Short-term debt$9.50M$9.50M$9.50M$9.50M$0
Long-term debt$1.39B$1.57B$1.59B$1.60B$0
Total debt$1.40B$1.57B$1.60B$1.61B$0
Total liabilities$1.74B$2.02B$2.04B$1.98B$193.70M
Shareholders' equity-$650.60M-$738.30M-$821.70M-$891.40M$594.30M
Net debt$1.17B$1.30B$1.28B$1.28B$0
Shares outstanding58.50M57.71M57.33M57.06M—
Cash flow statement
Operating cash flow$191.70M$35.70M$67.70M$412.20M$456.30M
Capital expenditure$9.30M$15.80M$26.50M$23.60M$36.80M
Free cash flow$182.40M$19.90M$41.20M$388.60M$419.50M
Investing cash flow-$9.30M-$15.80M-$26.50M-$24.00M-$39.20M
Financing cash flow-$226.70M-$73.40M-$48.70M-$48.00M-$417.10M
Depreciation & amortization$40.70M$36.20M$32.60M$31.70M$38.30M
Stock-based compensation$31.60M$26.30M$21.50M$18.70M$12.80M
Dividends paid$35.00M$34.50M$34.40M$8.60M$0

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.